CanSino Biologics Inc (CJH) - Net Assets
Based on the latest financial reports, CanSino Biologics Inc (CJH) has net assets worth €4.95 Billion EUR (≈ $5.79 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.18 Billion ≈ $8.39 Billion USD) and total liabilities (€2.22 Billion ≈ $2.60 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CJH tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.95 Billion |
| % of Total Assets | 69.02% |
| Annual Growth Rate | 41.75% |
| 5-Year Change | -42.05% |
| 10-Year Change | N/A |
| Growth Volatility | 116.71 |
CanSino Biologics Inc - Net Assets Trend (2016–2025)
This chart illustrates how CanSino Biologics Inc's net assets have evolved over time, based on quarterly financial data. See how many days can CanSino Biologics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CanSino Biologics Inc (2016–2025)
The table below shows the annual net assets of CanSino Biologics Inc from 2016 to 2025. For live valuation and market cap data, see CJH market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.95 Billion ≈ $5.79 Billion |
+0.89% |
| 2024-12-31 | €4.91 Billion ≈ $5.74 Billion |
-7.14% |
| 2023-12-31 | €5.29 Billion ≈ $6.18 Billion |
-27.03% |
| 2022-12-31 | €7.25 Billion ≈ $8.47 Billion |
-15.24% |
| 2021-12-31 | €8.55 Billion ≈ $9.99 Billion |
+40.80% |
| 2020-12-31 | €6.07 Billion ≈ $7.10 Billion |
+312.84% |
| 2019-12-31 | €1.47 Billion ≈ $1.72 Billion |
+192.75% |
| 2018-12-31 | €502.32 Million ≈ $587.26 Million |
-17.29% |
| 2017-12-31 | €607.33 Million ≈ $710.03 Million |
+183.17% |
| 2016-12-31 | €214.47 Million ≈ $250.74 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CanSino Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33535800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.43 Billion | 109.52% |
| Total Equity | €4.95 Billion | 100.00% |
CanSino Biologics Inc Competitors by Market Cap
The table below lists competitors of CanSino Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DongGuan Winnerway Industrial Zone Ltd
SHE:000573
|
$375.47 Million |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
$375.71 Million |
|
Benchmark Metals Inc
V:CEI
|
$375.87 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
$375.97 Million |
|
Aekyung Petrochemical Co Ltd
KO:161000
|
$375.29 Million |
|
Marine Electricals (India) Limited
NSE:MARINE
|
$375.18 Million |
|
Yaxing Chem
SHG:600319
|
$375.01 Million |
|
Gevo Inc
NASDAQ:GEVO
|
$374.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CanSino Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,909,872,000 to 4,953,620,000, a change of 43,748,000 (0.9%).
- Net income of 27,873,000 contributed positively to equity growth.
- Share repurchases of 7,306,000 reduced equity.
- New share issuances of 7,340,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €27.87 Million | +0.56% |
| Share Repurchases | €7.31 Million | -0.15% |
| Share Issuances | €7.34 Million | +0.15% |
| Other Changes | €15.84 Million | +0.32% |
| Total Change | €- | 0.89% |
Book Value vs Market Value Analysis
This analysis compares CanSino Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.12x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.87x to 0.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.78 | €2.42 | x |
| 2018-12-31 | €2.30 | €2.42 | x |
| 2019-12-31 | €6.60 | €2.42 | x |
| 2020-12-31 | €24.53 | €2.42 | x |
| 2021-12-31 | €32.31 | €2.42 | x |
| 2022-12-31 | €27.27 | €2.42 | x |
| 2023-12-31 | €21.32 | €2.42 | x |
| 2024-12-31 | €19.84 | €2.42 | x |
| 2025-12-31 | €20.05 | €2.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CanSino Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.63%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.45x
- Recent ROE (0.56%) is above the historical average (-10.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -23.24% | 0.00% | 0.00x | 1.52x | €-71.30 Million |
| 2017 | -10.61% | -34434.67% | 0.00x | 1.43x | €-125.18 Million |
| 2018 | -27.53% | -12215.64% | 0.00x | 1.58x | €-188.51 Million |
| 2019 | -10.66% | -6865.49% | 0.00x | 1.21x | €-303.82 Million |
| 2020 | -6.53% | -2138.90% | 0.00x | 1.11x | €-1.00 Billion |
| 2021 | 23.94% | 44.52% | 0.36x | 1.49x | €1.11 Billion |
| 2022 | -13.48% | -88.21% | 0.09x | 1.70x | €-1.58 Billion |
| 2023 | -28.11% | -429.55% | 0.04x | 1.77x | €-2.01 Billion |
| 2024 | -7.72% | -45.93% | 0.10x | 1.62x | €-869.87 Million |
| 2025 | 0.56% | 2.63% | 0.15x | 1.45x | €-467.49 Million |
Industry Comparison
This section compares CanSino Biologics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,659,440,547
- Average return on equity (ROE) among peers: -44.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CanSino Biologics Inc (CJH) | €4.95 Billion | -23.24% | 0.45x | $375.36 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $48.38 Billion | 9.77% | 0.93x | $1.13 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $170.06 Million | -9.56% | 0.06x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $7.31 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $73.36 Million |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more